Trials / Available
AvailableNCT06090331
89Zr-DFO-girentuximab Expanded Access Program (EAP)
An Expanded Access Program for the Non-invasive Detection of Clear Cell Renal Cell Carcinoma (ccRCC) in Patients With Renal Masses Utilizing 89Zirconium-labelled Girentuximab (89Zr-DFO-girentuximab)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- —
Summary
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 89Zr-DFO-girentuximab | Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days. |
Timeline
- First posted
- 2023-10-19
- Last updated
- 2025-07-08
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06090331. Inclusion in this directory is not an endorsement.